Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 26 of 5804
-
New drug DYNE-101 aims to ease muscle symptoms in DM1
Disease control Recruiting nowThe purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment basivarsen (DYNE-101) for the treatment of myotonic dystrophy 1 (DM1).
Phase: PHASE3 • Sponsor: Dyne Therapeutics • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New drug combo may help bladder cancer patients keep their bladder
Disease control Recruiting nowThis study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together as a bladder preservation approach to treat patients with muscle invasive bladder cancer. The study will compare these drugs to concurrent chemoradiotherapy that is usually use…
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Experimental CAR-T therapy takes on lupus and arthritis
Disease control Recruiting nowA single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA-UCAR-T cells in patients with autoimmune diseases. 36-72 patients are planned to be enrolled in the dose-escalation trial.
Phase: NA • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New immunotherapy combo aims to improve First-Line lung cancer treatment
Disease control Recruiting nowThis is a multicenter Phase II/III study evaluating the efficacy and safety of SCTB41 combined with chemotherapy versus tislelizumab combined with chemotherapy as first-line treatment in patients with driver-negative locally advanced or metastatic non-small cell lung cancer (NSCL…
Phase: PHASE2, PHASE3 • Sponsor: Sinocelltech Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo aims to stop advanced nose cancer from coming back
Disease control Not yet recruitingThe investigators have designed a multicenter, open-label, randomized controlled phase III clinical study of GAPP induction therapy followed by concurrent chemoradiotherapy and toripalimab maintenance therapy for high-risk locoregionally advanced nasopharyngeal carcinoma (stage I…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
4-Week TB pill could replace months of treatment for millions at risk
Prevention Recruiting nowA seamless, staged Phase II/III, open-label, multicenter, non-inferiority trial, to compare the efficacy and safety of 4 weeks of bedaquiline (BDQ) versus a a standard regimen for preventing regimen for preventing confirmed or probable tuberculosis disease (TBD) during 72 weeks o…
Phase: PHASE2, PHASE3 • Sponsor: Johns Hopkins University • Aim: Prevention
Last updated Jun 27, 2026 13:00 UTC
-
Gene therapy hope for toddlers with rett syndrome
Disease control Recruiting nowThe primary objectives of this study are to evaluate the safety, tolerability and preliminary efficacy of a single intrathecal (IT) dose of TSHA-102 in pediatric females with typical Rett syndrome.
Phase: PHASE3 • Sponsor: Taysha Gene Therapies, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Immunotherapy plus chemo aims to shrink stomach tumors before surgery
Disease control Recruiting nowThis study was a randomized, double-blind, multi-center phase III clinical trial to evaluate the event-free survival (EFS) of Adebrelimab with S-1 and oxaliplatin versus placebo combined with S-1 and oxaliplatin, and to evaluate the efficacy, safety and tolerability of the two co…
Phase: PHASE3 • Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
AI takes on breast cancer: could a computer pick better treatment than standard care?
Disease control Recruiting nowBased on total pathologic complete response (tpCR) after surgery, to evaluate the efficacy of an artificial intelligence model-matched anti-HER2 targeted treatment strategy (investigational arm) versus nab-paclitaxel + carboplatin + trastuzumab + pertuzumab (PCbHP, control arm) a…
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New malaria vaccine shows promise in african trial
⭐️ VACCINE ⭐️ Recruiting nowThis is a phase 2 clinical trial of a Plasmodium falciparum (Pf) late liver stage-arresting replication-competent (LARC) sporozoite (SPZ) vaccine (Sanaria® PfSPZ-LARC2 Vaccine) that will assess field efficacy in Africa. The PfSPZ comprising PfSPZ-LARC2 Vaccine contain a double d…
Phase: PHASE2 • Sponsor: Sanaria Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:01 UTC
-
New mRNA vaccine combo aims to prevent lung cancer recurrence in High-Risk patients
Disease control Recruiting nowResearchers are looking for new ways to treat high-risk, localized non-small cell lung cancer (NSCLC) that has been removed with surgery. People with high-risk, localized NSCLC are often treated with surgery. Researchers want to learn if participants can receive 1 or 2 trial tre…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New radioactive drug aims to slow advanced prostate cancer in major trial
Disease control Recruiting nowThe intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can a second CAR T-Cell infusion beat lymphoma that returns?
⭐️ CURE ⭐️ TerminatedThis research study is designed to evaluate the effects of retreatment with CTL019/CTL119 in patients with late relapse of B-cell lymphomas.
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: ⭐️ CURE ⭐️
Last updated Jul 24, 2026 00:00 UTC
-
HPV vaccine may stop precancerous lesions from returning
Prevention Not yet recruitingRandomized, placebo-controlled phase 3 trial to evaluate nonavalent HPV vaccine as a secondary prevention in patients treated for human papilloma virus related high-grade squamous intraepithelial lesions.
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Prevention
Last updated Jun 27, 2026 09:08 UTC
-
Kidney removal after immunotherapy may offer cure for select patients
⭐️ CURE ⭐️ Recruiting nowIn the current era of immune checkpoint inhibitors (ICI), the role and timing of nephrectomy remains unknown, particularly in cases of residual kidney disease after a major response at metastatic sites. In these cases, the rationale for a delayed nephrectomy is that it might achi…
Phase: NA • Sponsor: Institut Paoli-Calmettes • Aim: ⭐️ CURE ⭐️
Last updated Jun 27, 2026 11:03 UTC
-
Lung cancer trial seeks optimal immunotherapy schedule around surgery
Disease control Not yet recruitingThis is a randomized, open-label, multi-center Phase III clinical study aimed at head-to-head evaluating the clinical efficacy of three immunotherapy strategies, namely perioperative immunotherapy, neoadjuvant immunotherapy, and adjuvant immunotherapy using Toripalimab, in patien…
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for Hard-to-Treat breast cancer: phase 3 trial launches
Disease control Not yet recruitingThe purpose of this study is to compare the efficacy and safety of 9MW2821 versus investigator's choice of chemotherapy in participants with locally advanced or metastatic triple-negative breast cancer who have previously received taxane-based chemotherapy with or without immunot…
Phase: PHASE3 • Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Gene therapy could replace bone marrow transplants for rare immune disease
Disease control Not yet recruitingThe investigators propose to replace HLA- partially compatible allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for FHL type 3 patients, with autologous transplantation of immunoselected gene-modified CD34+ cells, combined with transduced autologous T-cell each time this…
Phase: PHASE1, PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New vaccine aims to shield kids from hand, foot, and mouth disease
⭐️ VACCINE ⭐️ Not yet recruitingThis multicenter, randomized, double-blind, placebo-controlled phase IIIa clinical trial aims to evaluate the protective efficacy , immunogenicity and safety of the Tetravalent Inactivated Enterovirus Vaccine (Vero Cell) in Children aged 6 to 71 months. Participants will be rand…
Phase: PHASE3 • Sponsor: Sinovac Biotech Co., Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:39 UTC
-
New hope for toddlers with rare brain tumors: targeted drug entrectinib tested
Disease control Recruiting nowThis clinical trial tests how well entrectinib works to treat patients less than 3 years of age with NTRK 1/2/3 or ROS1 fused, high grade glioma or other central nervous system (CNS) tumors.
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC